Breaking News, Collaborations & Alliances

Evotec, AstraZeneca in Kidney Disease Alliance

To explore compounds and targets with novel mechanisms with disease-modifying potential

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has signed a license and collaboration agreement with AstraZeneca to explore compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. AstraZeneca will have access to a selected series of molecules identified in Evotec’s systematic kidney disease initiative, which has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca will provide its pharmaceutical development expertise...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters